With several pharmaceutical products about to emerge from the pipeline, the firm sets its sights on becoming a `Merck of the year 2000'
"There was no doubt in my mind," recalls Zurawski, "that we were going to create a billion-dollar company."
But a decade later, as bio-technology's industry-wide sales reach a billion dollars for the first time, Centocor's annual revenue is only flirting with the $28 million mark, and the fulfillment of Zurawski's dream for his Malvern-based company still appears remote. Clearly, Centocor has a long way to go.
Nevertheless, the company - for reasons that go beyond revenue numbers - is widely recognized as a...
Interested in reading more?
Become a Member of
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?